Canada markets closed
LATEST UPDATE

NO WEEKLY BRIEF NEWSLETTER FOR THE WEEKEND OF OCT. 16-17

We are taking a short break, but we will be back next week. Stay tuned!

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.50+0.11 (+0.33%)
At close: 4:00PM EDT
33.50 0.00 (0.00%)
After hours: 04:00PM EDT

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Suite 200
Seattle, WA 98102
United States
855 466 8667
http://www.adaptivebiotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees622

Key Executives

NameTitlePayExercisedYear Born
Mr. Chad M. Robins M.B.A, M.B.A.Co-Founder, CEO & Chairman1.12M32.15M1974
Ms. Julie RubinsteinPres734.77k21.35M1972
Dr. Harlan S. Robins Ph.D.Co-Founder & Chief Scientific Officer747.65k12.57M1973
Mr. Chad M. Cohen CPAChief Financial Officer625.89k12.33M1975
Dr. Mark AdamsCOO & CTO403.4kN/A1967
Mr. Christopher Carlson Ph.D.FounderN/AN/AN/A
Karina CalzadillaVP of Investor RelationsN/AN/AN/A
Ms. Stacy L. TaylorSr. VP & Gen. CounselN/AN/A1960
Mr. Francis T. LoChief People OfficerN/AN/A1981
Mr. Malek Faham M.D., Ph.D.Sr. VP of InnovationN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Adaptive Biotechnologies Corporation’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.